IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2016-2023

FUNDING AMOUNT

2460143 USD

ABSTRACT

?DESCRIPTION (provided by applicant): The IKK/NF-?B pathway is clearly important in cancer initiation and progression, yet we do not fully understand the mechanisms whereby this pathway promotes the oncogenic phenotype and there are no specific inhibitors in the clinic. Complexity in cancer relative to NF-?B is raised by recent findings that both canonical and non- canonical NF-?B contribute to cancer progression, yet many studies only focus on the canonical pathway and then conclude that NF-?B is important in a particular cancer but not absolutely critical. Additionally, complexity is raised by results demonstrating that IKK has critical signaling functions separate from its ability to regulate NF-?B; for example we have found that IKK controls autophagy and mTORC1 signaling, both important in many cancers - yet thought to be mutually antagonistic. Recently we and others have established a role for IKK/NF-?B signaling in promoting the triple-negative breast cancer tumor initiating cell (TIC) phenotype, with evidence that both canonical and non-canonical IKK/NF-?B are important. Additionally, preliminary data in prostate cancer and glioma shows that IKK/NF-?B signaling is critical for the TIC phenotype. In all of these studies, NF-?B activity is enhanced/ altered in te TIC compartment, although a mechanism to explain this is not known. Preliminary data indicate a divergent IKK/NF-?B mechanism in PSA-low/AR-low and PSA-high/AR- high prostate cancer cells and indicates the involvement of IKK? in promoting reduced AR levels in the prostate TICs, potentially by direct phosphorylation. The PSA-low/AR-low prostate TICs are resistant to anti-AR therapy, suggesting that recurrence of prostate cancer is driven by survival/expansion of this cell compartment. Goals of this proposal are to: (i) characterize distinct contributions of canonical and non-canonical NF-?B on Ras-driven cancer and on breast cancer, (ii) identify transcriptional output related to canonical and non- canonical NF-?B in cancer, (iii) determine the involvement of NF-?B signaling in driving the tumor-initiating cell phenotype - focused on brain, glioma, and prostate cancer, with additional studies related the involvement of the IKK? pathway in promoting the PSA-lo/AR-lo TIC phenotype with the hypothesis that this drives resistance to anti-AR therapies, (iv) determine signaling events that promote an altered NF-?B response in TICs, (v) characterize the IKK signaling network, relating IKK signaling to control of autophagy and mTORC1 signaling in cancers, with the hypothesis that IKK functions drives both pathways to be active, (vi) determine mechanisms of resistance to IKK inhibitors - focused on compensation by remaining IKK/NF-?B signaling, and by kinome reprogramming and (vii) to facilitate movement of inhibitors into pre-clinical and clinical settings. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9416099

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "2460143"
    }, 
    "description": "?DESCRIPTION (provided by applicant): The IKK/NF-?B pathway is clearly important in cancer initiation and progression, yet we do not fully understand the mechanisms whereby this pathway promotes the oncogenic phenotype and there are no specific inhibitors in the clinic. Complexity in cancer relative to NF-?B is raised by recent findings that both canonical and non- canonical NF-?B contribute to cancer progression, yet many studies only focus on the canonical pathway and then conclude that NF-?B is important in a particular cancer but not absolutely critical. Additionally, complexity is raised by results demonstrating that IKK has critical signaling functions separate from its ability to regulate NF-?B; for example we have found that IKK controls autophagy and mTORC1 signaling, both important in many cancers - yet thought to be mutually antagonistic. Recently we and others have established a role for IKK/NF-?B signaling in promoting the triple-negative breast cancer tumor initiating cell (TIC) phenotype, with evidence that both canonical and non-canonical IKK/NF-?B are important. Additionally, preliminary data in prostate cancer and glioma shows that IKK/NF-?B signaling is critical for the TIC phenotype. In all of these studies, NF-?B activity is enhanced/ altered in te TIC compartment, although a mechanism to explain this is not known. Preliminary data indicate a divergent IKK/NF-?B mechanism in PSA-low/AR-low and PSA-high/AR- high prostate cancer cells and indicates the involvement of IKK? in promoting reduced AR levels in the prostate TICs, potentially by direct phosphorylation. The PSA-low/AR-low prostate TICs are resistant to anti-AR therapy, suggesting that recurrence of prostate cancer is driven by survival/expansion of this cell compartment. Goals of this proposal are to: (i) characterize distinct contributions of canonical and non-canonical NF-?B on Ras-driven cancer and on breast cancer, (ii) identify transcriptional output related to canonical and non- canonical NF-?B in cancer, (iii) determine the involvement of NF-?B signaling in driving the tumor-initiating cell phenotype - focused on brain, glioma, and prostate cancer, with additional studies related the involvement of the IKK? pathway in promoting the PSA-lo/AR-lo TIC phenotype with the hypothesis that this drives resistance to anti-AR therapies, (iv) determine signaling events that promote an altered NF-?B response in TICs, (v) characterize the IKK signaling network, relating IKK signaling to control of autophagy and mTORC1 signaling in cancers, with the hypothesis that IKK functions drives both pathways to be active, (vi) determine mechanisms of resistance to IKK inhibitors - focused on compensation by remaining IKK/NF-?B signaling, and by kinome reprogramming and (vii) to facilitate movement of inhibitors into pre-clinical and clinical settings.", 
    "endDate": "2023-01-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.4897743", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "4897743"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R35CA197684"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "clinic", 
      "non-canonical NF-?B", 
      "canonical pathways", 
      "breast cancer", 
      "IKK inhibitors", 
      "cancer progression", 
      "movement", 
      "pathway", 
      "phenotype", 
      "particular cancer", 
      "Ras", 
      "inhibitors", 
      "direct phosphorylation", 
      "divergent IKK/NF-?B mechanism", 
      "triple-negative breast cancer tumors", 
      "role", 
      "study", 
      "AR-lo TIC phenotype", 
      "tumor", 
      "preliminary data", 
      "Additional studies", 
      "goal", 
      "Tumor Initiating Cells", 
      "progression", 
      "TiC", 
      "VII", 
      "cancer initiation", 
      "AR-low", 
      "cell compartment", 
      "IKK", 
      "results", 
      "example", 
      "transcriptional output", 
      "high prostate cancer cells", 
      "IKK function", 
      "TIC phenotype", 
      "IKK/NF-?B pathway", 
      "cancer relatives", 
      "ability", 
      "NF-?B", 
      "cancer", 
      "brain", 
      "TIC compartment", 
      "function", 
      "AR levels", 
      "events", 
      "hypothesis", 
      "glioma", 
      "cells", 
      "NF-?B activity", 
      "RECENT FINDINGS", 
      "pre", 
      "non- canonical NF-?B", 
      "mechanism", 
      "survival/expansion", 
      "applicants", 
      "IKK/NF-?B", 
      "PSA", 
      "description", 
      "altered NF-?B response", 
      "IKK/NF-kappaB", 
      "prostate cancer", 
      "resistance", 
      "AR therapy", 
      "autophagy", 
      "evidence", 
      "complexity", 
      "involvement", 
      "proposal", 
      "distinct contributions", 
      "kinome reprogramming", 
      "specific inhibitor", 
      "mTORC1", 
      "cell phenotype", 
      "prostate TICs", 
      "oncogenic phenotype", 
      "non-canonical IKK/NF-?B", 
      "PSA-lo", 
      "many cancers", 
      "III", 
      "AR-low prostate TICs", 
      "recurrence", 
      "clinical setting", 
      "therapy", 
      "compensation", 
      "control", 
      "network", 
      "anti-AR therapy", 
      "others", 
      "many studies"
    ], 
    "name": "IKK/NF-kappaB Signaling in Cancer:  Therapy, Resistance, and Tumor Initiating Cells", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.10698.36", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", 
          "type": "Organization"
        }, 
        "familyName": "BALDWIN", 
        "givenName": "ALBERT SIDNEY", 
        "id": "sg:person.0734430667.25", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0734430667.25", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.4897743"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_16.xml.gz", 
    "startDate": "2016-02-03T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9416099"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.4897743'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.4897743'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.4897743'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.4897743'


 

This table displays all metadata directly associated to this object as RDF triples.

137 TRIPLES      19 PREDICATES      113 URIs      104 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.4897743 schema:about anzsrc-for:2206
2 anzsrc-for:2211
3 schema:amount N6b9c996e422d4f669128c946227911d0
4 schema:description ?DESCRIPTION (provided by applicant): The IKK/NF-?B pathway is clearly important in cancer initiation and progression, yet we do not fully understand the mechanisms whereby this pathway promotes the oncogenic phenotype and there are no specific inhibitors in the clinic. Complexity in cancer relative to NF-?B is raised by recent findings that both canonical and non- canonical NF-?B contribute to cancer progression, yet many studies only focus on the canonical pathway and then conclude that NF-?B is important in a particular cancer but not absolutely critical. Additionally, complexity is raised by results demonstrating that IKK has critical signaling functions separate from its ability to regulate NF-?B; for example we have found that IKK controls autophagy and mTORC1 signaling, both important in many cancers - yet thought to be mutually antagonistic. Recently we and others have established a role for IKK/NF-?B signaling in promoting the triple-negative breast cancer tumor initiating cell (TIC) phenotype, with evidence that both canonical and non-canonical IKK/NF-?B are important. Additionally, preliminary data in prostate cancer and glioma shows that IKK/NF-?B signaling is critical for the TIC phenotype. In all of these studies, NF-?B activity is enhanced/ altered in te TIC compartment, although a mechanism to explain this is not known. Preliminary data indicate a divergent IKK/NF-?B mechanism in PSA-low/AR-low and PSA-high/AR- high prostate cancer cells and indicates the involvement of IKK? in promoting reduced AR levels in the prostate TICs, potentially by direct phosphorylation. The PSA-low/AR-low prostate TICs are resistant to anti-AR therapy, suggesting that recurrence of prostate cancer is driven by survival/expansion of this cell compartment. Goals of this proposal are to: (i) characterize distinct contributions of canonical and non-canonical NF-?B on Ras-driven cancer and on breast cancer, (ii) identify transcriptional output related to canonical and non- canonical NF-?B in cancer, (iii) determine the involvement of NF-?B signaling in driving the tumor-initiating cell phenotype - focused on brain, glioma, and prostate cancer, with additional studies related the involvement of the IKK? pathway in promoting the PSA-lo/AR-lo TIC phenotype with the hypothesis that this drives resistance to anti-AR therapies, (iv) determine signaling events that promote an altered NF-?B response in TICs, (v) characterize the IKK signaling network, relating IKK signaling to control of autophagy and mTORC1 signaling in cancers, with the hypothesis that IKK functions drives both pathways to be active, (vi) determine mechanisms of resistance to IKK inhibitors - focused on compensation by remaining IKK/NF-?B signaling, and by kinome reprogramming and (vii) to facilitate movement of inhibitors into pre-clinical and clinical settings.
5 schema:endDate 2023-01-31T00:00:00Z
6 schema:funder https://www.grid.ac/institutes/grid.48336.3a
7 schema:identifier N3d31a081c2264769ac53fb2d6be929fb
8 Ne9ca94d6c50b434eb1d9993949f06c2a
9 schema:inLanguage en
10 schema:keywords AR levels
11 AR therapy
12 AR-lo TIC phenotype
13 AR-low
14 AR-low prostate TICs
15 Additional studies
16 III
17 IKK
18 IKK function
19 IKK inhibitors
20 IKK/NF-?B
21 IKK/NF-?B pathway
22 IKK/NF-kappaB
23 NF-?B
24 NF-?B activity
25 PSA
26 PSA-lo
27 RECENT FINDINGS
28 Ras
29 TIC compartment
30 TIC phenotype
31 TiC
32 Tumor Initiating Cells
33 VII
34 ability
35 altered NF-?B response
36 anti-AR therapy
37 applicants
38 autophagy
39 brain
40 breast cancer
41 cancer
42 cancer initiation
43 cancer progression
44 cancer relatives
45 canonical pathways
46 cell compartment
47 cell phenotype
48 cells
49 clinic
50 clinical setting
51 compensation
52 complexity
53 control
54 description
55 direct phosphorylation
56 distinct contributions
57 divergent IKK/NF-?B mechanism
58 events
59 evidence
60 example
61 function
62 glioma
63 goal
64 high prostate cancer cells
65 hypothesis
66 inhibitors
67 involvement
68 kinome reprogramming
69 mTORC1
70 many cancers
71 many studies
72 mechanism
73 movement
74 network
75 non- canonical NF-?B
76 non-canonical IKK/NF-?B
77 non-canonical NF-?B
78 oncogenic phenotype
79 others
80 particular cancer
81 pathway
82 phenotype
83 pre
84 preliminary data
85 progression
86 proposal
87 prostate TICs
88 prostate cancer
89 recurrence
90 resistance
91 results
92 role
93 specific inhibitor
94 study
95 survival/expansion
96 therapy
97 transcriptional output
98 triple-negative breast cancer tumors
99 tumor
100 schema:name IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
101 schema:recipient Nb22770f7c70f4feca543354fc9bc6b76
102 sg:person.0734430667.25
103 https://www.grid.ac/institutes/grid.10698.36
104 schema:sameAs https://app.dimensions.ai/details/grant/grant.4897743
105 schema:sdDatePublished 2019-03-07T12:04
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher Na399bd69195943b5a749dc4b8b9243b3
108 schema:startDate 2016-02-03T00:00:00Z
109 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9416099
110 sgo:license sg:explorer/license/
111 sgo:sdDataset grants
112 rdf:type schema:MonetaryGrant
113 N3d31a081c2264769ac53fb2d6be929fb schema:name nih_id
114 schema:value R35CA197684
115 rdf:type schema:PropertyValue
116 N6b9c996e422d4f669128c946227911d0 schema:currency USD
117 schema:value 2460143
118 rdf:type schema:MonetaryAmount
119 Na399bd69195943b5a749dc4b8b9243b3 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 Nb22770f7c70f4feca543354fc9bc6b76 schema:member sg:person.0734430667.25
122 schema:roleName PI
123 rdf:type schema:Role
124 Ne9ca94d6c50b434eb1d9993949f06c2a schema:name dimensions_id
125 schema:value 4897743
126 rdf:type schema:PropertyValue
127 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
128 rdf:type schema:DefinedTerm
129 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
130 rdf:type schema:DefinedTerm
131 sg:person.0734430667.25 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
132 schema:familyName BALDWIN
133 schema:givenName ALBERT SIDNEY
134 rdf:type schema:Person
135 https://www.grid.ac/institutes/grid.10698.36 schema:name UNIV OF NORTH CAROLINA CHAPEL HILL
136 rdf:type schema:Organization
137 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...